Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARCAGY/ GINECO GROUP
The main purpose of this research study is to find out if treatment of early relapse of ovarian or fallopian tube or peritoneal cancer with paclitaxel (Taxol\*) weekly administered, in lower doses in combination with topotecan (Hycamtin\*) or carboplatin will improve efficacy compared to weekly administration of paclitaxel in monotherapy. Tolerance in the three groups will be compared.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients aged \> 18
Histologically proven diagnosis of cancer of the ovary, the fallopian tube or peritoneum
Disease in progression under treatment or within 6 months after a first or second platinum-based line
A period of 3 weeks between last chemotherapy and inclusion
Measurable disease (Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup \[GCIG\] criteria)
ECOG performance status \< 2
Life expectancy of at least 12 weeks
You may not be if
Previously received weekly administration of paclitaxel chemotherapy
Involved in a trial within the last 30 days
Previously received a bone marrow autogreffe or irradiation of the abdomen within 5 years, due to intensive chemotherapy
Prior diagnosis of malignancy
History of ischemic cardiopathy, congestive heart failure (New York Heart Association \[NYHA\] \> 2), arrhythmia, hypertension, or significant valvulopathy
Pre-existing motor or sensory neurologic pathology or symptoms National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade \> 2
Bone marrow, renal, or hepatic insufficiency
Severe active infection or occlusive or sub-occlusive disease
History of symptomatic brain metastases
Fertile women not using adequate contraceptive methods
Pregnant or breast feeding women
Hypersensitivity to compounds chemically related to paclitaxel, topotecan, or carboplatin
Clareo Health | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
